The tariff classification of BHV-1500, BHV-1510, and BHV-1530 from China
No Headquarters ruling in this index revokes or modifies this ruling. That is not confirmation that it is still in effect: this index does not hold every Headquarters ruling. Confirm its current status with CBP before relying on it (ruling on CBP CROSS). Text last read from CBP on Nov 21, 2026.
Key passages, quoted from the ruling
- The applicable subheading for the BHV-1500, BHV-1510, and BHV-1530 will be 9817.85.01, HTSUS, which provides for “Prototypes to be used exclusively for development, testing, product evaluation, or quality control purposes.” The general rate of duty will be free.
Ruling text
In your letter dated March 30, 2026, you requested a tariff classification ruling on BHV-1500, BHV-1510, and BHV-1530. This ruling request was submitted by Kirti Jadeja, Deloitte Tax LLP. BHV-1500 consists of Brentuximab, a recombinant humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) directed against a cluster of differentiation (CD) 30 conjugated to the monomethyl auristatin E (MMAE), a microtubule-disrupting agent.
The product attacks cells that contain CD30 and gets into the tumor cells to stop its ability to grow and divide, resulting in death of the cancer cells. In your letter, you indicated the BHV-1500 will be imported as the BHV-1500 Active Pharmaceutical Ingredient (API) and as the BHV-1500 drug product for investigational research and drug development purposes to conduct Phase 1 through Phase 3 clinical trials.
The BHV-1500 API will be formulated into the drug product for testing or for use in toxicology studies to evaluate safety and efficacy in disease treatment in living organisms. The BHV-1500 drug product will be used in Phase 1 through Phase 3 clinical trial studies to test for efficacy in treating lymphoma and other solid tumors.
BHV-1510 consists of a recombinant humanized immunoglobulin G1 (IgG1) anti-trophoblast cell surface antigen 2 (Trop-2) monoclonal antibody (BH-0006587), a cleavable linker-payload (BH-0006588) which includes a deoxyribonucleic acid (DNA) topoisomerase I inhibitor (TopoIx) payload (BHC-0080269). BHV-1510 binds to the Trop-2 receptor on cancer cell surfaces, killing tumor cancer cells.
In your letter, you indicated the BHV-1510 will be imported as the BHV-1510 API and BHV-1510 drug product for investigational research and drug development purposes to conduct Phase 1 through Phase 3 clinical trials. The BHV-1510 API will be formulated into the drug product for testing or for use in toxicology studies to evaluate safety and efficacy in disease treatment in living organisms.
The BHV-1510 drug product will be used in Phase 1 through Phase 3 clinical trial studies to test for efficacy in treating tumors. BHV-1530 is an ADC of a specific anti-FGFR3 human monoclonal antibody (mAb), BHC-0080276, conjugated through site-specific conjugation to a novel topoisomerase I (Topo I) inhibitor, free payload (TopoIx) (BHC-70080269).
BHV-1530 is designed to target tumors with FGFR3 alterations, overexpression, or fusions, and is anticipated to be potentially effective against tumors exhibiting these FGFR3-related abnormalities. In your letter, you indicated the BHV-1530 will be imported as the BHV-1530 API and BHV-1530 drug product for investigational research and drug development purposes to conduct Phase 1 clinical trials.
In a follow-up email to this office, you stated that if Phase 1 clinical trials will be successful, it will move to Phase 2 and 3 clinical trials. The BHV-1530 API will be formulated into the drug product for testing or for use in toxicology studies to evaluate safety and efficacy in disease treatment in living organisms. The BHV-1530 drug product will be used in Phase 1 through Phase 3 clinical trial studies to test for efficacy in treating solid tumors.
The text above is an excerpt. The official ruling, with its letterhead, signature and any attachments, is on CBP CROSS (N360154).